Alnylam Pharmaceuticals, Inc.
ALNY
$304.67
$6.092.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.17% | 18.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.17% | 18.42% | |||
| Cost of Revenue | -30.91% | 19.69% | |||
| Gross Profit | 6.69% | 18.15% | |||
| SG&A Expenses | -18.75% | 33.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.50% | 20.85% | |||
| Operating Income | 117.19% | -36.74% | |||
| Income Before Tax | 78.55% | -78.49% | |||
| Income Tax Expenses | 114.41% | -3,890.68% | |||
| Earnings from Continuing Operations | 31.38% | 24.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 31.38% | 24.92% | |||
| EBIT | 117.19% | -36.74% | |||
| EBITDA | 135.70% | -44.61% | |||
| EPS Basic | 31.66% | 25.23% | |||
| Normalized Basic EPS | 79.12% | -80.23% | |||
| EPS Diluted | 31.66% | 25.44% | |||
| Normalized Diluted EPS | 79.12% | -80.23% | |||
| Average Basic Shares Outstanding | 0.43% | 0.41% | |||
| Average Diluted Shares Outstanding | 0.43% | 0.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||